Pemigatinib was approved in 2021 in Europe for treatment of adults with locally advanced or metastatic CCA with an FGFR2 fusion or rearrangement that progressed after ≥1 prior line of systemic therapy [7]. The gene discussed is FGFR2; the disease is cholangiocarcinoma.